Veracyte (NasdaqGM:VCYT) reported new predictive data on its Decipher Prostate Genomic Classifier in very high-risk ...

Add Yahoo as a preferred source to see more of our stories on Google. b' Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023 ...

Hello everyone. I am Tetsuya Kubota, Director of Kubota Clinic Matsudo Goko and a urology specialist.It can be quite a shock ...

Add Yahoo as a preferred source to see more of our stories on Google. The global statistics are terrifying. Prostate cancer is the fourth most common cancer in all populations, the second most common ...

The Decipher genomic test could help doctors decide which high-risk prostate cancer patients need abiraterone hormone therapy ...

Effective cancer screening protocols can dramatically alter outcomes for patients. Prostate cancer, for example, has been one of the most common cancers among men in the United States for decades. In ...

Proteins present in men’s blood could give clues to prostate cancer risk years before diagnosis. View on euronews ...

Current prostate specific antigen (PSA) testing "may not effectively target testing to those most likely to benefit, raising concerns about overtesting" warn researchers from the University of Oxford ...

IF GETTING A screening test for prostate cancer isn’t on your radar, it’s probably because the government guidelines essentially told you not to bother back in 2012. But prostate cancer rates have ...

To date, men undergoing screening through the measurement of prostate-specific antigen (PSA) levels have had a significant reduction in neoplastic mortality. Because of its low specificity, however, ...

A physician emphasized how emotional support, reliable health information and caregiver involvement can encourage men to take ...

Prostate cancer (PCa) represents a major health burden across Europe, and screening is already widely performed, predominantly through opportunistic PSA ...